

Results Presentation
Fiscal 2016

Kyowa Hakko Kirin Co., Ltd.

FY 2016 Highlights

Nobuo Hanai, Ph. D. President and CEO

Financial review 2017 Forecasts

Kazuyoshi Tachibana, Managing Executive Officer

R & D review Business Topics

Nobuo Hanai, Ph. D. President and CEO

This document contains certain forward-looking statements relating to such items as the company's (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasonable assumptions made by the company in making its forecasts, but actual results in practice may differ substantially due to uncertain factors.

These uncertain factors include, but are not limited to, potential risks of the business activities of the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of side effects, legal regulation risks, product defect risks, risks of changes to prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.

This document contains information on pharmaceutical products (including products under development), but its contents should not be construed as promotion, advertising or as a medical recommendation.

In FY2016, sales and profits declined in the Pharmaceuticals and Bio-Chemicals businesses YoY due to the drug price revision, yen appreciation and increased R&D expenses. FY2016 business plan was largely achieved.

- Despite well-performing sales of the new products, including G-Lasta[®], NOURIAST[®], Dovobet[®] and Onglyza[®], the sales of pharmaceuticals business declined in Japan due to the drug price revision that led to a decline in sales of our long-term prescription products, resulting in domestic net sales decline of ¥4.3 billion YoY.
- The overseas sales in the Pharmaceuticals business decreased by ¥ 13.8 billion YoY due to the decrease in licensing revenue, yen appreciation and other factors.
- Due to the steady progress of late-stage development products, R&D expense in the Pharmaceuticals business increased by ¥ 2.2 billion YoY.
- In the Bio-Chemical business, sales decreased by ¥ 5.2 billion YoY, and operating income decreased by ¥ 2.8 billion YoY due to the strong yen and more intensive competition in Asian market

Financial review

Summary of 2016 results (consolidated)

KYOWA KIRIN

Despite strong sales of new products, the consolidated sales and profits declined due to the reduced licensing revenue, increased R&D expense and continued yen appreciation.

(Unit: ¥bn)	FY2015 results	FY2016 results	Change	FY2016 forecast	Rate of progress
Net sales	364.3	343.0	-21.2 (-6%)	344.0	100%
Operating Income <i>Operating margin</i>	43.7 [12.0%]	31.6 [9.2%]	-12.1 (-28%)	32.0	99%
Ordinary income	39.2	26.3	-12.8 (-33%)	26.0	102%
Net profit	29.7	18.6	-11.1 (-37%)	18.0	104%


(Profits stated after amortization of goodwill. Figures rounded down)

(Rate of progress of FY 2016 sales forecast, released on July 21, 2016)

✓ Ordinary income and net profit declined due to a decrease in operating income.

Summary of FY2016 consolidated results: Analysis of YoY profit changes

2016 net profit: Analysis of YoY changes



Summary of FY2016 financial results by segment

KYOWA KIRIN

In the Pharmaceuticals business, despite strong sales of new products, the sales and profits declined due to the drug price revision, reduced licensing revenue and increased R&D expenses.


In the Bio-Chemicals businesses, sales and profits declined due to the yen appreciation.

(Unit: ¥bn)		FY2015 results	FY2016 results	Change
Pharmaceuticals business	Net sales	279.2	263.2	-16.0 (-6%)
	Operating income <i>Operating margin</i>	36.2 [13.0%]	26.3 [10.0%]	-9.8 (-27%)
Bio-Chemicals business	Net sales	88.8	83.6	-5.2 (-6%)
	Operating income <i>Operating margin</i>	8.1 [9.1%]	5.3 [6.4%]	-2.8 (-35%)

(Profits stated after amortization of goodwill. Figures rounded down)

Pharmaceuticals business: FY2016 Analysis of YoY changes


Net sales



Net sales (- ¥16.0bn)

- Domestic pharmaceutical products (- ¥4.3bn):
 - New products including G-Lasta and NOURIAST grew steadily.
 - Our key product NESP decreased in sales due to the impact of drug price revision.
 - Sales of long-term prescription products such as ALLELOCK decreased due to the impact of drug price revision and penetration of generics.
- Technology licensing, etc. (- ¥6.2bn), Currency effects (- ¥0.1bn)
 - The decrease is attributable to the upfront payment (\$45mn) under the option agreement for KHK4563 made in the previous year and decrease in royalties, etc.
- Overseas sales (- ¥4.1bn), Currency effects (- ¥10.9bn)
 - KKI* (- ¥3.3bn): Despite the growth of Abstral and PecFent, its overall sales decreased due to the yen appreciation.

Operating income



Operating income (- ¥9.8bn)

- Gross profits (- ¥14.0bn), Currency effects (- ¥8.7bn)
 - Decrease in licensing revenues and continued yen appreciation
- SG&A (+ ¥6.4bn), Currency effects (+ ¥6.7bn)
 - Decrease in expenses due to the upfront payment for in-licensing in the previous year and continued yen appreciation
 - Increase in expenses due to the in-licensing of Moventig.
- R&D expenses (- ¥2.2bn), Currency effects (+ ¥2.5bn)
 - Increase in expenses for late-stage developments, etc.

* On February 22, 2016, ProStrakan Group plc's company name was changed to Kyowa Kirin International plc (KKI).

Pharmaceuticals business: Domestic sales of key products

KYOWA KIRIN

Despite the increased sales of new products, the sales of domestic pharmaceutical products decreased YoY due to the impact of the drug price revision, etc.


Product name, other information	FY2015 results	FY2016 results	Change	Reason for change	FY2016 Forecast	Rate of Progress*
NESP®	57.5	56.3	- 1.1 (- 2%)	(+) Steady growth of the market (-) Drug price revisions	56.5	100%
REGPARA®	18.2	19.9	+ 1.7 (+ 10%)	(+) Steady growth of the market	19.7	101%
ALLELOCK®	22.1	18.1	- 3.9 (- 18%)	(-) Drug price revisions (-) Market penetration of generics	17.8	102%
Patanol®	12.8	12.9	+ 0.1 (+ 1%)		12.8	101%
G-Lasta®	10.3	15.5	+ 5.1 (+ 50%)	(+) Steady penetration of the market	15.9	98%
NOURIAST®	5.3	7.2	+ 1.8 (+ 35%)	(+) Steady penetration of the market	7.0	103%
Technology out-licensing	11.9	5.9	- 6.0 (- 51%)	(-) The upfront payment received in the previous year (-) Decrease in royalties	6.4	91%

* Rate of progress compared to 2016 sales forecasts (as of July 29, 2016)


(Unit: ¥bn, figures rounded down)

Bio-Chemicals business: FY2016: Analysis of YoY profit

Net sales



Operating income



Net sales (- ¥5.2bn)

- Overseas sales (- ¥4.1bn):, Currency effects (- ¥4.1bn)
 - Americas (- ¥0.6bn), Currency effects (- ¥1.1bn): growth in amino acids for cell culture medium
 - Europe (- ¥1.6bn), Currency effects (- ¥1.7bn): The reduction in sales resulting from transfer of cosmetics raw materials business was compensated by steady sales of APIs* and infusion use amino acids
 - Asia and others (- ¥1.8bn), Currency effects (- ¥1.2): Intensified sales competition of APIs in the Asian market
- Pharma / health-food use (- ¥0.6bn)
 - Reactionary reduction in sales resulting from massive shipment of APIs for generics in the previous year
- Mail order sales, etc. (+ ¥0.6bn)
 - The mail-order sale business stayed strong supported by sales growth of new products
- Kyowa Pharma Chemical (- ¥1.1bn):
 - A decline compared with last year when significant shipments of pharmaceutical intermediate occurred. The sales of some products with narrow profit margin were terminated.

Operating income (- ¥2.8bn)

- Gross profit (- ¥3.3bn), Currency effects (- ¥2.5bn)
 - The decrease is attributable to the continued yen appreciation, reactionary reduction in domestic sales resulting from massive shipment of APIs for generics in the previous year and the reduction in gross profit margins due to intensified competition in the Asian market
- SG&A (+ ¥0.5bn), Currency effects (+ ¥0.5bn)
 - Reduction in SG&A due to the continued yen appreciation

*API: active pharmaceutical ingredient

2017 Forecasts


We forecast an increase in sales due to the licensing revenues and growth of the new products in Japan and overseas, and an increase in profits due to the reduction in costs for late-stage development products, despite continuing aggressive R&D investment.

(Unit: ¥bn)	FY2016 results	FY2017 forecasts	Change (%)
Net sales	343.0	344.0	+ 0.9 (+0%)
Operating income <i>Operating margin</i>	31.6 [9.2%]	35.0 [10.2%]	+ 3.3 (+11%)
Ordinary income	26.3	30.0	+ 3.6 (+14%)
Net income	18.6	19.0	+ 0.3 (+2%)

(Profits stated after amortization of goodwill. Figures rounded down)

Summary of FY2017 consolidated forecasts: Analysis of YoY profit changes


FY2017 net income forecast: Analysis of YoY changes



Pharmaceuticals business: FY2017 forecasts

(Unit: ¥bn)	FY2016 results	FY2017 forecasts	Change
Net sales	263.2	264.0	0.7 (+0%)
Operating income <i>Operating margin</i>	26.3 [10%]	29.0 [11.0%]	2.6 (+10%)

Operating income YoY change



(+)

- Increase in licensing revenue and strong sales of new products in domestic and overseas markets
- Currency effect of SG&A (excl. R&D expenses)
- Reduction in expenses for late-stage development products

(-)


- Market penetration of competing products and generics and currency effect
- Preparation expense for marketing of the product developed by KKI

(Figures rounded down. Operating income stated after amortization of goodwill.)

Bio-Chemical business: FY2017 forecasts

(Unit: ¥bn)	FY2016 results	FY2017 forecasts	Change
Net sales	83.6	83.0	- 0.6 (-1%)
Operating income <i>Operating margin</i>	5.3 [6.4%]	6.0 [7.2%]	0.6 (+ 13%)

Operating income YoY change



(+)

- Increase in gross profit margin due to growth in sales of pharmaceutical and health food materials
- Reduction in costs for manufacturing pharmaceutical and health food materials
- Increase in gross profit margin driven by growth of mail order sales

(-)

- Increase in sales promotion costs for mail order sales

(Figures rounded down. Operating income stated after amortization of goodwill.)

Shareholder returns policy

- **Dividend payout ratio**

From 2016 to 2018, pay out constant dividends in compliance with 2016-2020 Mid-Term Business Plan, which set a target dividend payout ratio of 40% on the basis of the net profit before amortization of goodwill

- **Acquisition of treasury stock**

Implement flexibly in response to market environment and finances

Planned dividends for period

**Based on the company's shareholder returns policy,
the company expects to pay a year-end dividend of
¥12.50 per share
(Including an interim dividend of ¥12.50 per share,
the total dividend will be ¥25 per share)**

* Profits before amortization of goodwill

R&D review

Domestic:

- **Announcement of results of interim efficacy analysis of Phase 2 clinical study of RTA 402 targeting chronic kidney disease with type-2 diabetes (May)**
- **Initiation of Phase 2 study of KHK4563 targeting eosinophilic chronic rhinosinusitis (June)**
- **Approval received for fully human anti-IL-17 receptor A antibody KHK4827 (brand name in Japan: LUMICEF®) (July) and launch (September)**
- **Initiation of Phase 2 study of KW-6356 targeting Parkinson's disease (November)**
- **Initiation of Phase 1 study of KHK4083 targeting ulcerative colitis (December)**

Overseas:

- **Initiation of Phase 1/2 trials of nivolumab (Bristol-Myers Squibb) in combination with KW-0761 targeting solid tumors (February, U.S.)**
- **Announcement of results from Phase 3 trials of benralizumab/KHK4563 targeting asthma (May)**
- **Announcement of results from Phase 2 study of KW-0761 targeting adult T cell leukemia-lymphoma (June, ASCO)**
- **Initiation of Phase 3 study of AMG531 targeting aplastic anemia (June, Japan, Korea)**
- **Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA) for KRN23 targeting pediatric X-Linked Hypophosphatemia (June, U.S.)**
- **Initiation of Phase 2 study of KRN23 targeting TIO or ENS (June, Japan, Korea)**
- **Initiation of Phase 2 study of KHK4083 targeting ulcerative colitis (June, North America, Europe)**

Overseas (cont.):

- **Initiation of Phase 1 study of KHK2455 in combination with KW-0761 targeting solid tumors (October, U.S.)**
- **Initiation of Phase 3 study of KRN23 targeting pediatric patients with X-Linked Hypophosphatemia (October in North America, EU, Japan, Korea and Australia)**
- **Announcement of top-line results of Phase 3 clinical study of KW-6002 targeting Parkinson's disease (December, U.S., Europe)**
- **EMA acceptance for review of marketing authorization application for KRN23 targeting X-Linked Hypophosphatemia (December, Europe)**
- **Initiation of Phase 3 study of KHK4827 targeting psoriasis (January, Korea)**

KW-6356

Indication	Country/ region	Development stage (Scheduled trial completion date)		Estimated enrollment
		Phase 2		
Parkinson's disease	Japan	(2018/12)		150

2

Estimated no. of patients: Japan: approx. 160,000¹ patients

¹ Ministry of Health, Labour and Welfare: 2014 Patient survey (illness classification)

ClinialTrials.gov identifier:

² NCT02939391

KW-6356: Target product profile

Mode of Action: Non-dopaminergic PD* medication based on A2A receptor antagonism

Early stage: PD medication used as monotherapy or adjunct therapy for improving motor symptoms

Advanced stage: PD medication used as adjunct therapy for improving motor symptoms and motor complications



Early stage PD (without motor complications)

Monotherapy

Combination therapy

Advanced stage PD (with motor complications)

Monotherapy

Combination therapy

KW-6356 (target product profile)

- Improve motor symptoms when used as monotherapy
- Improve motor symptoms and complications when used as adjunct therapy. (-> adjunct concomitant medication when L-dopa or DA* has no sufficient effect)
- Explore efficacy for non-motor symptoms

NOURIAST® (Indication)

Improve WO* phenomenon in advanced stage
 => Concomitant medication in adjunct to L-dopa

*PD: Parkinson's disease; DA: dopamine agonists; WO: wearing off

KW-6353 Phase II Study Design:

Title: A Study of KW-6356 in Subject With Early PD
(double-blind, placebo-controlled study in patients* with early PD)



Primary Outcome Measures: Change from baseline in MDS-UPDRS Part III score
(motor symptoms)

Assessment period: 12 weeks

Estimated Enrollment: 150

*Patients with PD who are classified into 1, 2 or 3 according to the modified Hoehn and Yahr scale and have an MDS-UPDRS Part III score of at least 15.

KW-0761 (hematological cancer)¹

Indication		Country/ region	Development stage (Scheduled trial completion date)			Estimated enrollment
			Phase 2	Phase 3	Application	
ATL	Relapsed/ refractory	U.S., Europe, others	(2016/11)			3
CTCL	Relapsed/ refractory	U.S., Europe, Japan, others		(2017/2)		4

Annual incidence per disease: U.S.: CTCL: approx. 1,500² patients

¹ Launched in Japan (brand name POTELIGEO®)

² SEER Data (2001-2007)

ClinialTrials.gov identifier:

³ NCT01626664; ⁴ NCT01728805

KW-0761 (solid tumor)

Indication	Country/ region	Concomitant Drug	Development stage (Scheduled trial completion date)	Partner	Estimated enrollment	
			Phase 1			
Solid tumor	U.S.	Durvalumab or Tremelimumab	(2017/11)	AstraZeneca	108	1
	U.S.	PF-05082566	(2019/8)	Pfizer	70	2
	Japan	Nivolumab	(2017/10)	ONO PHARMACEUTICAL Bristol-Myers Squibb	108	3
	U.S.	Nivolumab	(2018/3)	Bristol-Myers Squibb	188	4
	U.S.	Docetaxel	2016/12	-	13	5
	U.S.	KHK2455	(2019/8)	-	50	6

ClinicalTrials.gov identifier:

¹ NCT02301130; ² NCT02444793; ³ NCT02476123; ⁴ NCT02705105; ⁵ NCT02358473; ⁶ NCT02867007

KW-6002 ¹

Indication	Country/region	Development stage (Scheduled trial completion date)		Estimated enrollment
		Phase 3	Application	
Parkinson's disease	U.S., Europe, others	2016/10		613 ⁴

Estimated no. of patients: Japan: approx. 160,000 ²

Estimated no. of treatable patients: U.S.: approx. 800,000 ³

¹ Launched in Japan (brand name: NOURIAST®)

² Ministry of Health, Labour and Welfare: 2014 Patient survey (illness classification)

³ Study by Decision Resources

ClinialTrials.gov identifier:

⁴ NCT01968031

KRN23

Indication	Country/region	Development stage (Scheduled trial completion date)		Partner	Estimated enrollment		
		Phase 2	Phase 3				
XLH	Pediatric	U.S., Europe	(2018/12)		Ultragenyx Pharmaceutical (North America, Europe)	50	2
		U.S.	(2017/12)			13	3
		N.A., Europe, Japan, Korea, Australia		(2018/9)		60	4
	Adult	U.S.	(2016/9)			25	5
		U.S., Europe, Japan, Korea		(2017/3)		134	6
		N.A., Europe, Japan, Korea		(2017/8)		14	7

Estimated no. of patients: Adults: Japan: approx. 5,000, Europe: approx. 12,000, U.S.: approx. 12,000¹
 Pediatric: Japan: approx. 1,000, Europe: approx. 3,000, U.S.: approx. 3,000¹

¹ Estimate based on reported prevalence of 1 in 20,000 people

ClinicalTrials.gov identifier:

² NCT02163577; ³ NCT02750618; ⁴ NCT02915705; ⁵ NCT02312687; ⁶ NCT02526160; ⁷ NCT02537431

N. A.: North America

© Kyowa Hakko Kirin Co., Ltd.

KRN23

Indication	Country/region	Development stage (Scheduled trial completion date)		Partner	Estimated enrollment
		Phase 2	Phase 3		
TIO/ENS	U.S.	(2016/9)		Ultragenyx Pharmaceutical (U.S., Europe)	15 ³
	Japan / Korea	(2017/7)			6 ⁴

Estimated no. of patients: Japan: approx. 30¹, U.S.: approx.500 - 1,000²

¹ 2010 Ministry of Health, Labour and Welfare Epidemiological Research on abnormalities in Hormone Receptor Mechanisms

² Survey by Ultragenyx Pharmaceutical

ClinicalTrials.gov identifier:

³ NCT02304367; ⁴ NCT02722798

Business Topics


- **Establishment of Kyowa Kirin Frontier Co., Ltd.**

ATL	Adult T-cell Leukemia/Lymphoma
CCR4	Chemokine (C-C motif) Receptor 4
CTCL	Cutaneous T-Cell Lymphoma
ENS	Epidermal Nevus Syndrome
TIO	Tumor Induced Osteomalacia
XLH	X-linked Hypophosphatemia

APPENDIX



Appendix: Analysis of FY2016 profit comparison to forecasts

2016 Net income: comparison to forecasts



Appendix: Pharmaceuticals business

FY2017 forecasts: Analysis of YoY changes



Net sales (+ ¥0.7bn)

- Domestic pharmaceutical products (- ¥7.4bn):
 - New products including G-Lasta® and NOURIAST® grow steadily
 - Our key product NESP® increases in sales
 - Sales of long-term prescription products such as ALLELOCK® decrease due to the penetration of generics.
- Technology licensing, etc. (+ ¥2.1bn), Currency effects +¥0.0bn
- Overseas sales (- ¥1.1bn), Currency effects - ¥2.3bn
 - KKI (- ¥2.0bn): Despite the growth of Abstral, PecFent and Sancuso, its overall sales decrease due to the yen appreciation
- Others (+ ¥7.2bn)
 - Licensing revenues of overseas subsidiary increase


Operating income (+ ¥2.6bn)

- Gross profits (+ ¥3.6bn), Currency effects - ¥1.5bn
 - (profits up) Increase in licensing revenues, and increase in sales of new products in domestic and overseas markets
 - (profits down) Decrease in sales due to the strong competition and penetration of the generic drugs in domestic market
- SG&A (- ¥2.1bn), Currency effects + ¥2.2bn
 - (costs up) Expenses incurred in preparation for launch of development products at KKI, etc.
 - (costs down) Yen appreciation
- R&D expenses (+ ¥1.2bn), Currency effects - ¥0.0bn
 - (costs down) Decrease in R&D expenses especially for late stage development

Appendix: Bio-Chemicals business

FY2017 forecasts: Analysis of YoY profit changes


Net sales



Net sales (- ¥0.6bn)

- Overseas sales (+ ¥0.8bn): Currency effects -¥0.0bn
- Americas: (+ ¥0.9bn), Currency effects (+ ¥0.1bn): increase due to growth in health food use amino acids
- Europe (- ¥0.5), Currency effects (- ¥0.1bn): decrease due to in reduction of infusion use amino acids shipment, etc.
- Asia and others (+ ¥0.4bn), Currency effects (- ¥0.0bn): growth in health food use and infusion use amino acids, etc.
- Pharmaceutical and health food materials(+ ¥0.3bn): Steady growth in both pharmaceutical and health food use materials
- Consumer products(+ ¥0.8bn): Growth in mail order sales
- Kyowa Pharma Chemical (- ¥0.7bn): End of sales of low-margin agency sales, etc.

Operating income



Operating income (+ ¥0.6bn)

- Gross profit (+ ¥1.7bn), Currency effects - ¥0.0bn
- Increase in gross profit margin due to growth in domestic and overseas sales of pharmaceutical and health food materials
- Reduction in manufacturing costs of pharmaceutical and health food materials to domestic and overseas markets
- Increase in gross profit margin due to growth of mail-order sales, etc.
- SG&A (- ¥0.8bn), Currency effects + ¥0.0bn
- Increase in sales promotion costs for mail order sales, etc.
- R&D expenses (- ¥0.2bn):

Development code	Reference bio medical product		Country/region	Development stage			
	Generic name	Brand name		Phase 1	Phase 2	Phase 3	
FKB327	Adalimumab	HUMIRA	U.S., others				1
FKB238	Bevacizumab	Avastin	United Kingdom				2
Not disclosed	Not disclosed	Not disclosed	Not disclosed	Determined target product			

Biosimilar pharmaceutical products are developed by *FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.*

ClinialTrials.gov identifier: ¹ NCT02260791; ² NCT02810457

² Development is currently conducted by Centus Biotherapeutics Limited.

Development progress with outlicensed compounds

Name	Partner	Phase			Filing	Remarks
		I	II	III		
Tivozanib	AVEO				Europe	Advanced Renal Cell Cancer (VEGF receptor inhibitor) (KRN951)
Benralizumab (MEDI-563)	AstraZeneca /MedImmune					Asthma (Anti-IL-5R antibody) (KHK4563)
						COPD POTELLIGENT®
RGI-2001	REGiMMUNE	Phase1/2				Immunosuppressive

(as of January 24, 2017)

Average Exchange Rate

Average exchange rate	2015 Results	2016 Results	Change	FY2017 Forecast
¥/\$	¥121	¥109	- ¥12	¥110
¥/€	¥135	¥121	- ¥14	¥120
¥/£	¥185	¥150	- ¥35	¥140

FY2016 Currency Effects (YoY)

Segment	Currency	Net sales	Operating income
Pharmaceuticals business	\$	- ¥0.24bn	+ ¥1.20bn
	€	- ¥0.09bn	- ¥0.04bn
	£	- ¥8.79bn	+ ¥0.28bn
Bio-Chemicals business	\$	- ¥2.06bn	- ¥1.14bn
	€	- ¥1.72bn	- ¥0.89bn
	£	-	-

Estimated Exchange Rate Sensitivity of the (consolidated) Earnings Forecast for 2017*

Currency	Changes	Impact on Net Sales	Impact on Operating Income
¥/\$	+ ¥ 1	-¥0.30bn	-¥0.13bn
¥/€	+ ¥ 1	-¥0.13bn	-¥0.06bn
¥/£	+ ¥ 1	-¥0.25bn	+¥0.02bn

* The values represent estimated cumulative outcome over the consecutive 12 months for a potential change in Japanese yen exchange rate.

KYOWA KIRIN

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

**If you have any inquiries regarding this presentation, please call:
Corporate Communications Department, Kyowa Hakko Kirin Co., Ltd.
Tel: +81-3-5205-7206**